On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics.

被引：0
|
作者：
Brockmöller, J
Kirchheiner, J
Henckel, H
Meineke, I
Roots, I
机构：
[1] Univ Gottingen, D-3400 Gottingen, Germany
[2] Humboldt Univ, D-1086 Berlin, Germany
[3] Charite Med Ctr, Berlin, Germany
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2003.11.250
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P67 / P67
页数：1
相关论文
共 50 条
  • [21] CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour
    Saarikoski, ST
    Sata, F
    Husgafvel-Pursiainen, K
    Rautalahti, M
    Haukka, J
    Impivaara, O
    Järvisalo, J
    Vainio, H
    Hirvonen, A
    PHARMACOGENETICS, 2000, 10 (01): : 5 - 10
  • [22] CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Hiken, Eliah J.
    Poweleit, Ethan A.
    Keane, Corey
    Desta, Zeruesenay
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S197 - S197
  • [23] A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
    Blake, C. M.
    Kharasch, E. D.
    Schwab, M.
    Nagele, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 394 - 399
  • [24] The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report
    Kuzin, Maxim
    Scharrer, Isabel
    Nolan, Daniele
    Baumgartner, Markus
    Paulzen, Michael
    Schoretsanitis, Georgios
    Xepapadakos, Franziskos
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 127 (04) : 354 - 357
  • [25] Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics
    Oishi, Masayo
    Chiba, Koji
    Malhotra, Bimal
    Suwa, Toshio
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (09) : 1456 - 1463
  • [26] The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer
    AbdelRahman, SZ
    Anwar, WA
    AbdelAal, WE
    Ghoneim, MA
    Au, WW
    CANCER LETTERS, 1997, 119 (01) : 115 - 122
  • [27] Voriconazole dose-related hepatotoxicity in a patient with an ultra-rapid CYP2C19 metabolizer genotype
    Pena-Lorenzo, D.
    Rebollo, N.
    Garcia-Casanueva, J. C.
    Martin-Gil, M.
    Otero, M. J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1538 - 1538
  • [28] Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?
    Vormfelde, SV
    Bitsch, A
    Meineke, I
    GundertRemy, UM
    Gleiter, CH
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 387 - 390
  • [29] Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?
    S. V. Vormfelde
    A. Bitsch
    I. Meineke
    U. M. Gundert-Remy
    C. H. Gleiter
    European Journal of Clinical Pharmacology, 1997, 52 : 387 - 390
  • [30] Impact of CYP2D6 metabolizer phenotype on the safety profile of paliperidone ER
    Dunbar, Fiona
    Chue, Pierre
    Fu, Dong-Jing
    Huang, Qiqing
    Franc, Monique-Andree
    Cohen, Nadine
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 83S - 83S
12345